中国医疗健康：中国临床前 CRO 行业趋势-China Healthcare _ Expert call takeaways_ China‘s preclinical CRO industry trends

Summary of Expert Call on China's Preclinical CRO Industry Trends Industry Overview - Industry: China's preclinical Contract Research Organization (CRO) industry - Current Trends: Significant recovery in industry demand observed in Q4 2025, continuing into Q1 2026 with expectations of strong growth for the full year 2026 [1][10] Key Insights Demand and Order Volume - Order Volume Growth: Anticipated increase of approximately 15% quarter-over-quarter (QoQ) in Q1 2026 and over 25% year-over-year (YoY); full-year growth forecasted between 15% and 30% YoY, largely dependent on the non-human primate (NHP) supply situation [1][10] - Execution of Orders: Most new orders in H1 2026 are scheduled for execution in H2 2026, indicating a backlog due to tight NHP supply [3][10] Pricing Trends - Service Fees: Service fees have rebounded to about 80% of standard quotes in late 2025, with expectations to return to 100% for medium- to long-term orders [1][12] - NHP Prices: Current NHP prices have risen to Rmb150,000-160,000 in Q1 2026 from Rmb130,000-140,000 at the end of Q4 2025, with projections to reach Rmb170,000-180,000 in 2026 and potentially surpass Rmb190,000 in 2027 if supply remains constrained [2][8] Supply Constraints - NHP Supply Issues: The supply of age-appropriate NHPs is critically low, estimated at less than 20,000 nationwide, while demand is around 20,000 annually. The expert noted that the NHP base has not been replenished effectively after previous high demand cycles [2][7] - Import Challenges: Increasing imports from Southeast Asia are constrained by regulatory approvals and quarantine processes, limiting shipments to 1,000-2,000 NHPs at a time [2][9] Market Dynamics - Industry Concentration: The tightening of preclinical research qualifications by the government is expected to increase industry concentration, as larger firms secure NHP resources early [3][17] - Demand from Drug Types: Current demand is primarily driven by biologics, particularly antibodies and antibody-drug conjugates (ADCs), with some demand from small nucleic acids and oligopeptides [14] Capacity and Competition - CRO Capacity: Overall capacity is aligned with demand, with only a few firms expanding facilities. Major companies are securing NHP resources through early contracts [3][15] - Emerging Companies: New firms, often backed by investment institutions, are entering the market with significant incremental demand, focusing on innovative drug development [16][17] Risks and Considerations - Market Risks: Potential risks include unexpected price cuts from government programs, intensified competition, and regulatory changes that could impact operations and profitability [18] Conclusion The expert call highlighted a recovering preclinical CRO industry in China, driven by increasing demand for NHPs and biologics, but also underscored significant supply constraints and rising prices that could impact future growth and profitability. The tightening of regulations may lead to greater industry concentration, favoring established players.